These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 19303394

  • 1. Bone morphogenetic protein-7 and Gremlin: New emerging therapeutic targets for diabetic nephropathy.
    Zhang Y, Zhang Q.
    Biochem Biophys Res Commun; 2009 May 22; 383(1):1-3. PubMed ID: 19303394
    [Abstract] [Full Text] [Related]

  • 2. In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7.
    Zhang Q, Shi Y, Wada J, Malakauskas SM, Liu M, Ren Y, Du C, Duan H, Li Y, Li Y, Zhang Y.
    PLoS One; 2010 Jul 22; 5(7):e11709. PubMed ID: 20661431
    [Abstract] [Full Text] [Related]

  • 3. Decrease of bone morphogenetic protein-7 (BMP-7) and its type II receptor (BMP-RII) in kidney of type 1-like diabetic rats.
    Yeh CH, Chang CK, Cheng MF, Lin HJ, Cheng JT.
    Horm Metab Res; 2009 Aug 22; 41(8):605-11. PubMed ID: 19440953
    [Abstract] [Full Text] [Related]

  • 4. Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis.
    Mezzano S, Droguett A, Burgos ME, Aros C, Ardiles L, Flores C, Carpio D, Carvajal G, Ruiz-Ortega M, Egido J.
    Nephrol Dial Transplant; 2007 Jul 22; 22(7):1882-90. PubMed ID: 17403698
    [Abstract] [Full Text] [Related]

  • 5. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
    Sugimoto H, Grahovac G, Zeisberg M, Kalluri R.
    Diabetes; 2007 Jul 22; 56(7):1825-33. PubMed ID: 17456853
    [Abstract] [Full Text] [Related]

  • 6. Expression of gremlin, a bone morphogenetic protein antagonist,is associated with vascular calcification in uraemia.
    Jara A, Chacón C, Burgos ME, Droguett A, Valdivieso A, Ortiz M, Troncoso P, Mezzano S.
    Nephrol Dial Transplant; 2009 Apr 22; 24(4):1121-9. PubMed ID: 19028757
    [Abstract] [Full Text] [Related]

  • 7. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy.
    Walsh DW, Roxburgh SA, McGettigan P, Berthier CC, Higgins DG, Kretzler M, Cohen CD, Mezzano S, Brazil DP, Martin F.
    Biochim Biophys Acta; 2008 Jan 22; 1782(1):10-21. PubMed ID: 17980714
    [Abstract] [Full Text] [Related]

  • 8. Antagonists of bone morphogenetic proteins in kidney disease.
    Yanagita M.
    Curr Opin Investig Drugs; 2010 Mar 22; 11(3):315-22. PubMed ID: 20178045
    [Abstract] [Full Text] [Related]

  • 9. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes aristolochic acid-induced epithelial-to-mesenchymal transition (EMT) in HK-2 cells.
    Li Y, Wang Z, Wang S, Zhao J, Zhang J, Huang Y.
    Toxicology; 2012 Jul 16; 297(1-3):68-75. PubMed ID: 22525892
    [Abstract] [Full Text] [Related]

  • 10. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy.
    Dolan V, Murphy M, Sadlier D, Lappin D, Doran P, Godson C, Martin F, O'Meara Y, Schmid H, Henger A, Kretzler M, Droguett A, Mezzano S, Brady HR.
    Am J Kidney Dis; 2005 Jun 16; 45(6):1034-9. PubMed ID: 15957132
    [Abstract] [Full Text] [Related]

  • 11. Role of growth factors in diabetic kidney disease.
    Chiarelli F, Gaspari S, Marcovecchio ML.
    Horm Metab Res; 2009 Aug 16; 41(8):585-93. PubMed ID: 19452424
    [Abstract] [Full Text] [Related]

  • 12. [Relation between bone matrix proteins and monocyte chemoattractant protein-1 in renal small artery in diabetic nephropathy rats].
    Zhao AJ, Huang SM, Ou ST, Liu F, Chen ZJ, Hu ZX, Tang WX.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 May 16; 43(3):414-9. PubMed ID: 22812249
    [Abstract] [Full Text] [Related]

  • 13. [Potential therapeutic targets for diabetic nephropathy].
    Makino Y, Haneda M.
    Nihon Rinsho; 2009 Aug 16; 67(8):1627-35. PubMed ID: 19768953
    [Abstract] [Full Text] [Related]

  • 14. Gremlin: an example of the re-emergence of developmental programmes in diabetic nephropathy.
    Lappin DW, McMahon R, Murphy M, Brady HR.
    Nephrol Dial Transplant; 2002 Aug 16; 17 Suppl 9():65-7. PubMed ID: 12386293
    [Abstract] [Full Text] [Related]

  • 15. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy.
    Wang SN, Lapage J, Hirschberg R.
    J Am Soc Nephrol; 2001 Nov 16; 12(11):2392-2399. PubMed ID: 11675415
    [Abstract] [Full Text] [Related]

  • 16. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.
    Budhiraja S, Singh J.
    Fundam Clin Pharmacol; 2008 Jun 16; 22(3):231-40. PubMed ID: 18485142
    [Abstract] [Full Text] [Related]

  • 17. Gremlin1 preferentially binds to bone morphogenetic protein-2 (BMP-2) and BMP-4 over BMP-7.
    Church RH, Krishnakumar A, Urbanek A, Geschwindner S, Meneely J, Bianchi A, Basta B, Monaghan S, Elliot C, Strömstedt M, Ferguson N, Martin F, Brazil DP.
    Biochem J; 2015 Feb 15; 466(1):55-68. PubMed ID: 25378054
    [Abstract] [Full Text] [Related]

  • 18. The binding of the bone morphogenetic protein antagonist gremlin to kidney heparan sulfate: Such binding is not essential for BMP antagonism.
    Tatsinkam AJ, Rune N, Smith J, Norman JT, Mulloy B, Rider CC.
    Int J Biochem Cell Biol; 2017 Feb 15; 83():39-46. PubMed ID: 27979781
    [Abstract] [Full Text] [Related]

  • 19. Gremlin Regulates Podocyte Apoptosis via Transforming Growth Factor-β (TGF-β) Pathway in Diabetic Nephropathy.
    Wang XB, Zhu H, Song W, Su JH.
    Med Sci Monit; 2018 Jan 09; 24():183-189. PubMed ID: 29315280
    [Abstract] [Full Text] [Related]

  • 20. Gremlin and renal diseases: ready to jump the fence to clinical utility?
    Mezzano S, Droguett A, Lavoz C, Krall P, Egido J, Ruiz-Ortega M.
    Nephrol Dial Transplant; 2018 May 01; 33(5):735-741. PubMed ID: 28992340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.